Day One Biopharmaceuticals Stock Price | DAWN Stock Quote, News, and History | Markets Insider (2024)

14.96-0.23-1.48%

After-market 05:21:59 PM EDT 4/24/2024BTT

Plus500. 81% of retail CFD accounts lose money

15.19-1.47-8.80%

Official Close 03:59:59 PM EDT 4/24/2024BTT

NewsAnalyst DataAnalyst OpinionsInsider ActivityDividend Calendar



New: Online Broker Comparison!Learn more about the best online brokers in our new comparison! Find out more!

On Tuesday 04/23/2024 the closing price of the Day One Biopharmaceuticals Inc Registered Shs share was $15.19 on BTT.Compared to the opening price on Tuesday 04/23/2024 on BTT of $15.69, this is a drop of 3.33%.Day One Biopharmaceuticals Inc Registered Shs's market capitalization is $1.45 B by 87.38 M shares outstanding.

Day One Biopharmaceuticals Stock Snapshot

14.55

Bid

100.00

Bid Size

100.00

Ask Size

4/24/2024

Date

5:21 PM

Time

0.00

Volume

15.19

Prev. Close

0.00

Open

1.45 B

Market Cap

87.38 M

Number of Shares

9.65

52 Week Low

18.10

52 Week High

0.00

Dividend

0.00

Dividend Yield

-6.16

P/E Ratio

67.46

Free Float in %

-2.64

EPS 2024

3.26

Book Value per Share

-1.45

Cash Flow per Share

Day One Biopharmaceuticals NewsMore News

TipRanks

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Day One Biopharmaceuticals (DAWN) and Roche Holding AG (OtherRHHVF)

TipRanks

Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Day One Biopharmaceuticals (DAWN)

TipRanks

Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Biogen (BIIB) and Neurocrine (NBIX)

TipRanks

Buy Rating Affirmed for Day One Biopharmaceuticals Following FDA Approval of Ojemda

Historical Prices for Day One Biopharmaceuticals

Loading..
DateOpenCloseDaily HighDaily Low

Price change over selected period:0%0

Day One Biopharmaceuticals Analyst Data

Total Analysts: 33

Buy Ratings: 32 Neutral Ratings: 0 Sell Ratings: 1

Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}

Price *Price Target

Lowest: 9.00 Median: 40.79 Highest: 62.00

*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Day One Biopharmaceuticals Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
DateAnalystRatingPrice
04/24/24H.C. Wainwright & Co.Maintained Buy$50gut
04/24/24Needham & Company, LLCMaintained Buy$33gut
04/22/24J.P. MorganMaintained Buy$36gut
03/26/24Piper SandlerMaintained Buy$40gut
02/28/24Piper SandlerMaintained Buy$40gut
02/27/24Goldman SachsMaintained Buy$44gut
02/27/24Oppenheimer & Co. Inc.Maintained Holdneutral
11/07/23Wedbush Morgan Securities Inc.Maintained Buy$35gut
11/07/23Needham & Company, LLCMaintained Buy$34gut
09/12/23Wedbush Morgan Securities Inc.Maintained Buy$38gut
09/12/23Needham & Company, LLCMaintained Buy$34gut
08/08/23Needham & Company, LLCMaintained Buy$34gut
08/08/23Goldman SachsMaintained Buy$54gut
08/08/23H.C. Wainwright & Co.Maintained Buy$50gut
06/05/23Wedbush Morgan Securities Inc.Maintained Buy$38gut
06/05/23Needham & Company, LLCMaintained Buy$40gut
06/05/23H.C. Wainwright & Co.Maintained Buy$50gut
05/18/23H.C. Wainwright & Co.Maintained Buy$45gut
05/08/23Needham & Company, LLCMaintained Buy$40gut
05/02/23Needham & Company, LLCMaintained Buy$44gut
04/25/23Bank of America Merrill LynchDowngraded to Sell$9schlecht
04/05/23Needham & Company, LLCMaintained Buy$44gut
03/07/23Needham & Company, LLCMaintained Buy$48gut
03/07/23H.C. Wainwright & Co.Maintained Buy$45gut
02/08/23CapitalOne southcoastMaintained Buy$40gut
02/03/23Oppenheimer & Co. Inc.Maintained Holdneutral
01/09/23Goldman SachsMaintained Buy$62gut
01/09/23Piper SandlerMaintained Buy$45gut
01/09/23H.C. Wainwright & Co.Maintained Buy$45gut
12/15/22H.C. Wainwright & Co.Maintained Buy$35gut
12/14/22Needham & Company, LLCMaintained Buy$40gut
12/05/22Goldman SachsMaintained Buy$45gut
12/01/22Bank of America Merrill LynchMaintained Buy$34gut
06/21/22Piper SandlerMaintained Buy$40gut
06/14/22Wedbush Morgan Securities Inc.Maintained Buy$35gut

Day One Biopharmaceuticals Estimates* in USD

20242025202620272028
Revenue1280257387588
Dividend0.000.00---
Dividend Yield (in %)0.00 %0.00 %---
EPS-2.64-1.94-0.410.662.09
P/E Ratio-5.67-7.72-36.1422.777.17
EBIT-242-185-2698275
EBITDA-252-2217--
Net Profit-227-182-2959206
Net Profit Adjusted-228-196-40--
Pre-Tax Profit-230-179-4107275
Net Profit (Adjusted)-214-12415--
EPS (Non-GAAP) ex. SOE-2.46-1.80-0.251.022.85
EPS (GAAP)-2.64-1.94-0.410.662.09
Gross Income1388216349504
Cash Flow from Investing00000
Cash Flow from Operations-205-11031263410
Cash Flow from Financing119119133
Cash Flow per Share-1.45-1.600.11--
Free Cash Flow-137-3062--
Free Cash Flow per Share-1.51-0.051.50--
Book Value per Share3.264.414.14--
Net Debt-93-220-272--
Research & Development Exp.147149144148150
Capital Expenditure00000
Selling, General & Admin. Exp.105119129137150
Shareholder’s Equity225323355524940
Total Assets2843674045841,010
Previous Quarter
ending 03/31/24		Current Quarter
ending 06/30/24		Next Quarter
ending 09/30/24		Current Year
ending 12/31/24		Next Year
ending 12/31/25
Earnings Estimates
No. of Analysts9991111
Average Estimate-0.663 USD-0.691 USD-0.644 USD-2.637 USD-1.939 USD
Year Ago-0.590 USD-0.610 USD-0.540 USD-2.370 USD-2.637 USD
Publish Date5/9/20248/6/202411/4/2024--
Revenue Estimates
No. of Analysts7891111
Average Estimate0 USD1 USD4 USD12 USD80 USD
Year Ago----12 USD
Publish Date5/9/20248/6/202411/4/2024--

* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Day One Biopharmaceuticals Insider Activity

NameDateshares tradedshares heldPricetype (sell/buy)option
Blackman Samuel C.04/17/202410,000.001,174,662.0016.02Sell No
Blackman Samuel C.03/24/202410,000.001,184,662.0016.01Sell No
Blackman Samuel C.03/10/202430,000.001,194,662.0015.24Sell No
Blackman Samuel C.02/26/202420,000.001,224,662.0016.11Sell No
Bender Jeremy02/15/20247,615.00721,813.0015.25Sell No
Blackman Samuel C.02/15/20242,258.001,244,662.0015.25Sell No
Dubow Adam02/15/20243,242.0016,585.0015.25Sell No
York Charles N II02/15/20242,666.00277,754.0015.25Sell No
Bender Jeremy02/14/202411,687.00729,428.00n/aBuy No
Bender Jeremy02/14/20244,750.00717,741.00n/aBuy No
Bender Jeremy02/14/20243,562.00712,991.00n/aBuy No
Blackman Samuel C.02/14/20241,187.001,239,421.00n/aBuy No
Blackman Samuel C.02/14/20241,437.001,240,858.00n/aBuy No
Blackman Samuel C.02/14/20246,062.001,246,920.00n/aBuy No
Dubow Adam02/14/20243,687.0019,827.00n/aBuy No
York Charles N II02/14/20246,625.00280,420.00n/aBuy No
York Charles N II02/14/20242,250.00273,795.00n/aBuy No
Dubow Adam02/14/20241,750.0016,140.00n/aBuy No
Dubow Adam02/14/20242,962.0014,390.00n/aBuy No
York Charles N II02/14/20241,375.00271,545.00n/aBuy No
York Charles N II11/15/2023956.00270,170.0011.69Sell No
Dubow Adam11/15/20235,313.0011,428.0011.69Sell No
Blackman Samuel C.11/15/2023709.001,238,234.0011.69Sell No
York Charles N II11/14/20232,250.00271,126.00n/aBuy No
York Charles N II11/14/20231,375.00268,876.00n/aBuy No

Day One Biopharmaceuticals Dividend Calendar

DateNameDividend*yieldCurrency
2023Day One Biopharmaceuticals Inc Registered Shs0.000.00USD
2022Day One Biopharmaceuticals Inc Registered Shs0.000.00USD
2021Day One Biopharmaceuticals Inc Registered Shs0.000.00USD
2020Day One Biopharmaceuticals Inc Registered ShsUSD
2019Day One Biopharmaceuticals Inc Registered ShsUSD

*Yield of the Respective Date

Day One Biopharmaceuticals Inc Registered Shs Calendar

EventEstimateInfoDate
Earnings Report-0.663 USD Q1 2024 Earnings Release05/09/2024
Annual General Meeting- Annual General Meeting05/23/2024
Earnings Report-0.691 USD Q2 2024 Earnings Release08/06/2024
Earnings Report-0.644 USD Q3 2024 Earnings Release11/04/2024
Earnings Report- Q4 2024 Earnings Release03/10/2025

Day One Biopharmaceuticals Inc Registered Shs Past Events

EventActual EPSInfoDate
Earnings Report -0.630 USDQ4 2023 Earnings Release02/26/2024

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Shareholder

Ownerin %
Freefloat67.46
Access Industries, Inc. (New York)14.80
RA Capital Management LP8.94
RA Capital Management LP8.94
Atlas Venture Life Science Advisors LLC8.71
The Vanguard Group, Inc.5.46
Vanguard Group, Inc. (Subfiler)5.29
Braidwell LP4.82
Franklin Advisers, Inc.4.81
State Street Corp.3.87
BlackRock Fund Advisors3.42
Pictet Asset Management Holding SA2.94
Viking Global Investors LP2.93
Canaan Management, Inc.2.85
Canaan Partners XI LLC2.85

Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Day One Biopharmaceuticals Stock Price | DAWN Stock Quote, News, and History | Markets Insider (2024)
Top Articles
Top 24 Best German Side Dishes With Recipes Made Just Like Oma
Modern Barn House - Milwicz Architekci
Astronomers Find New Mysterious Moons in Our Solar System Every Year. These Are The Weirdest.
Elecnor Deimos on LinkedIn: #far2019 #flightsystems #space
Latest Posts
The Top 5 Trends in Modern Barn House Design - Barndominiums Canada
Extra-Flaky Scallion Pancakes Recipe
Article information

Author: Greg O'Connell

Last Updated:

Views: 6769

Rating: 4.1 / 5 (42 voted)

Reviews: 81% of readers found this page helpful

Author information

Name: Greg O'Connell

Birthday: 1992-01-10

Address: Suite 517 2436 Jefferey Pass, Shanitaside, UT 27519

Phone: +2614651609714

Job: Education Developer

Hobby: Cooking, Gambling, Pottery, Shooting, Baseball, Singing, Snowboarding

Introduction: My name is Greg O'Connell, I am a delightful, colorful, talented, kind, lively, modern, tender person who loves writing and wants to share my knowledge and understanding with you.